David M. Irlbeck

1.5k total citations
17 papers, 889 citations indexed

About

David M. Irlbeck is a scholar working on Virology, Infectious Diseases and Hepatology. According to data from OpenAlex, David M. Irlbeck has authored 17 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Virology, 12 papers in Infectious Diseases and 5 papers in Hepatology. Recurrent topics in David M. Irlbeck's work include HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (5 papers). David M. Irlbeck is often cited by papers focused on HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (5 papers). David M. Irlbeck collaborates with scholars based in United States, United Kingdom and Canada. David M. Irlbeck's co-authors include Ronald Swanstrom, Michael R. Betts, Nancy Davis, E. Randall Lanier, Paul Sandstrom, Charles Craig, Amanda Smith, Jonathan Lipscomb, Michael Monsour and Xierong Wei and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Virology and The Journal of Infectious Diseases.

In The Last Decade

David M. Irlbeck

17 papers receiving 854 citations

Peers

David M. Irlbeck
Gayathri S. Athreya United States
Joseph P. Nkolola United States
Marie Leoz France
Tamara Bar-Magen Canada
Miranda Shehu-Xhilaga Australia
Takeo Kuwata Japan
S Goldstein United States
Isabel Olivares Spain
Catherine Jett United States
Valerie F. Boltz United States
Gayathri S. Athreya United States
David M. Irlbeck
Citations per year, relative to David M. Irlbeck David M. Irlbeck (= 1×) peers Gayathri S. Athreya

Countries citing papers authored by David M. Irlbeck

Since Specialization
Citations

This map shows the geographic impact of David M. Irlbeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Irlbeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Irlbeck more than expected).

Fields of papers citing papers by David M. Irlbeck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Irlbeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Irlbeck. The network helps show where David M. Irlbeck may publish in the future.

Co-authorship network of co-authors of David M. Irlbeck

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Irlbeck. A scholar is included among the top collaborators of David M. Irlbeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Irlbeck. David M. Irlbeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Salinas, Tomas Raul Wiche, Yuwei Zhang, Alexander Zhyvoloup, et al.. (2021). Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth. Proceedings of the National Academy of Sciences. 118(48). 25 indexed citations
2.
Tang, Jun, Stacey A. Jones, Jerry Jeffrey, et al.. (2017). Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms. Bioorganic & Medicinal Chemistry Letters. 27(12). 2689–2694. 19 indexed citations
3.
4.
Lee, Sook-Kyung, et al.. (2011). Interplay between Single Resistance-Associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor Sensitivity. Antimicrobial Agents and Chemotherapy. 56(2). 623–633. 25 indexed citations
5.
Johnson, Jeffrey A., LI Jin-fen, Xierong Wei, et al.. (2008). Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy. PLoS Medicine. 5(7). e158–e158. 291 indexed citations
6.
Irlbeck, David M., Heather Amrine‐Madsen, Kathryn M. Kitrinos, Celia C. LaBranche, & James F. Demarest. (2008). Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS. 22(12). 1425–1431. 19 indexed citations
7.
Underwood, Mark, Lisa Ross, David M. Irlbeck, et al.. (2008). Sensitivity of Phenotypic Susceptibility Analyses for Nonthymidine Nucleoside Analogues Conferred by K65R or M184V in Mixtures with Wild-Type HIV-1. The Journal of Infectious Diseases. 199(1). 84–88. 9 indexed citations
8.
Demarest, James F., Heather Amrine‐Madsen, David M. Irlbeck, & Kathryn M. Kitrinos. (2008). Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism. Antimicrobial Agents and Chemotherapy. 53(3). 1116–1123. 13 indexed citations
9.
Kitrinos, Kathryn M., Heather Amrine‐Madsen, David M. Irlbeck, J. Michael Word, & James F. Demarest. (2008). Virologic Failure in Therapy-Naive Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope. Antimicrobial Agents and Chemotherapy. 53(3). 1124–1131. 26 indexed citations
10.
Saavedra‐Lozano, Jesús, Francisco Sanz, María Luisa Navarro, et al.. (2006). Salvage Therapy With Abacavir and Other Reverse Transcriptase Inhibitors for Human Immunodeficiency-Associated Encephalopathy. The Pediatric Infectious Disease Journal. 25(12). 1142–1152. 7 indexed citations
11.
Bartlett, John, Judy Johnson, Néstor Sosa, et al.. (2006). Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(3). 284–292. 56 indexed citations
12.
Givens, Naomi, Christopher Stone, Philip Griffin, et al.. (2004). Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens. HIV Medicine. 5(6). 394–399. 30 indexed citations
13.
Resch, Wolfgang, et al.. (2003). Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrobial Agents and Chemotherapy. 47(2). 759–769. 44 indexed citations
14.
Davis, Nancy, Kevin Brown, Michael R. Betts, et al.. (2000). Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles. Journal of Virology. 74(1). 371–378. 160 indexed citations
15.
Davis, Nancy, Kevin Brown, Michael R. Betts, et al.. (2000). Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles. Journal of Virology. 74(7). 3430–3430. 31 indexed citations
16.
Irlbeck, David M., et al.. (1999). The HIV Type 1 Protease Inhibitor Saquinavir Can Select for Multiple Mutations that Confer Increasing Resistance. AIDS Research and Human Retroviruses. 15(4). 355–363. 26 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gayathri S. Athreya Breakdown of academic impact, for papers by Joseph P. Nkolola Breakdown of academic impact, for papers by Marie Leoz Breakdown of academic impact, for papers by Tamara Bar-Magen Breakdown of academic impact, for papers by Miranda Shehu-Xhilaga Breakdown of academic impact, for papers by Takeo Kuwata Breakdown of academic impact, for papers by S Goldstein Breakdown of academic impact, for papers by Isabel Olivares Breakdown of academic impact, for papers by Catherine Jett Breakdown of academic impact, for papers by Valerie F. Boltz
Rankless by CCL
2026